CommercialPrior AuthLow impact
[Virginia] Precertification list change notification
Anthem BCBS·VA · Hematology, Oncology, Pediatrics·Provider Bulletin
Effective date
Jan 1, 2027
We identified it
Jun 19, 2026
Summary
Anthem Blue Cross and Blue Shield is adding Gene Therapy for Wiskott-Aldrich Syndrome (MED.00161) to their precertification requirements effective January 1, 2027. This rare genetic disorder treatment will now require prior authorization before services can be rendered to avoid reimbursement complications.
Action Required
By January 1, 2027: Billing and clinical teams must update systems to require precertification for Gene Therapy for Wiskott-Aldrich Syndrome (criteria MED.00161) for Virginia Anthem BCBS members. Verify member eligibility through Availity Essentials at https://Availity.com or call the number on member ID card before rendering services. Failure to obtain precertification may result in reimbursement complications.